Inicio › Melanoma › California › Los Angeles
Ensayos clínicos de Melanoma en Los Angeles, CA
34 estudios para Melanoma buscan participantes en centros de Los Angeles y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
ReclutandoFase 1/2
- The Angeles Clinic and Research Institute (Melanoma), Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
ReclutandoFase 3
- University of California Los Angeles, Los Angeles
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
ReclutandoFase 2
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- y 1 más
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
ReclutandoFase 1/2
- University of Southern California, Los Angeles
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
ReclutandoFase 3
- USC Norris Comprehensive Cancer Center, Los Angeles
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
ReclutandoFase 3
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
ReclutandoFase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
ReclutandoFase 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
ReclutandoFase 1/2
- START Los Angeles, Los Angeles
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
ReclutandoFase 1
- The Angeles Clinic, Los Angeles
- UCLA, Los Angeles
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
ReclutandoFase 1/2
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Project: Every Child for Younger Patients With Cancer
ReclutandoEstudio observacional
- Children's Hospital Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Mattel Children's Hospital UCLA, Los Angeles
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
ReclutandoFase 1/2
- Children's Hospital Los Angeles, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
ReclutandoFase 1/2
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
ReclutandoFase 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ReclutandoFase 1
- START Los Angeles, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
ReclutandoFase 1/2
- Los Angeles Cancer Network, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
ReclutandoFase 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
The Multicentre Selective Lymphadenectomy Trial - 3
Reclutando
- Cedars-Sinai Medical Centre, Los Angeles
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
ReclutandoFase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
ReclutandoFase 1/2
- UCLA Medical Center, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
ReclutandoFase 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
Neoadjuvant Darovasertib in Primary Uveal Melanoma
ReclutandoFase 3
- Jules Stein Eye Institute, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Reclutando
- Oncology Institute for Hope and Innovation, Los Angeles
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
ReclutandoFase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
ReclutandoFase 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
ReclutandoFase 2/3
- The Angeles Clinic and Research Institute, Los Angeles
- University of California Los Angeles, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
ReclutandoFase 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
ReclutandoFase 2
- The Angeles Clinic at Cedars Sinai, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
ReclutandoFase 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- UCLA Health, Los Angeles
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
ReclutandoFase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Reclutando
- Los Angeles General Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
- y 2 más
Más información sobre Melanoma en MedlinePlus
Ensayos de Melanoma en otras ciudades
- Houston, TX59 estudios
- New York City, NY38 estudios
- Nashville, TN33 estudios
- Pittsburgh, PA31 estudios
- Boston, MA26 estudios
- Philadelphia, PA23 estudios
- San Francisco, CA22 estudios
- Atlanta, GA21 estudios
- Salt Lake City, UT21 estudios
- St. Louis, MO21 estudios
- Columbus, OH21 estudios
- Durham, NC21 estudios
Otros estudios en Los Angeles
- Cáncer de pulmón de células no pequeñas87 estudios
- Cáncer (todos los tipos)74 estudios
- Cáncer de seno73 estudios
- Cáncer de próstata61 estudios
- Cáncer del colon y del recto59 estudios
- Cáncer metastásico57 estudios
- Cáncer de ovario50 estudios
- Cáncer de pulmón45 estudios
- Carcinoma de células escamosas de cabeza y cuello42 estudios
- Cáncer de páncreas35 estudios
- Cáncer de endometrio34 estudios
- Cáncer de mama triple negativo27 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.